Celltrion Seo Jung-jin

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Nvidia Corp.’s Chief Executive Jensen Huang has asked SK Group Chairman Chey Tae-won to supply 12-layer HBM4 chips, the most advanced AI chips...

BTS Jin will open a pop-up titled “Running Wild to Happiness” from November 19 to December 1 at The Hyundai Seoul, marking the release o...

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

BTS Jin released “I'll Be There,” a preview track from his first solo album, on Friday, his agency Big Hit Music announced.“I'll B...

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...

The title track of the first solo album to be released by BTS member Jin is “Running Wild,” his agency Big Hit Music announced on Thursd...

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

South Korea's budget carrier Jin Air said on Friday that it will resume and expand its international flights for the upcoming winter season, focus...

HYBE Co. has suffered a fall of its share price for two consecutive days after its popular girl group NewJeans demanded their former creative direct...

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...

South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...

South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&...

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...

Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...

South Korea's low-cost carrier Jin Air announced on Friday that it will launch a new route between Busan and Nagoya, starting on Sept. 14, with dail...

South Korean gaming giant Krafton Inc. has hired former executives of not only global game developers but also tech leaders such as Apple Inc. and S...

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

Jeju Air Co., a leading South Korean low-cost carrier (LCC), will likely seek the acquisition and merger of a rival small airline operator amid inte...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korea’s largest biosimilar maker Celltrion Inc. said on Tuesday that its third plant in Sondgo, west of Seoul, is undergoing process val...

South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed...

South Korea's low-cost carrier (LCC) Jin Air announced on Wednesday that it received an A in the Sustinvest ESG (Environmental, Social, Governance) ...

South Korea’s National Pension Service (NPS) Chief Investment Officer Seo Won-joo has visited Japan and Singapore on his first overseas busine...

Korea Ginseng Corp. (KGC), wholly owned by South Korean tobacco giant KT&G Corp., announced on June 13 that it sells its red ginseng brand Jung ...

A legal battle between South Korea’s entertainment powerhouse HYBE Co. and the chief of its sublabel ADOR will likely drag on as the internati...

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...